Start here if you're new
what it is
Reviva is a 14-person biotech developing drug candidates for schizophrenia and other hard-to-treat diseases.
how it gets paid
Last year Reviva Pharma made n/a in revenue. Central nervous system was the main engine at $0M, or 20% of sales.
what just happened
Reviva’s latest quarter showed a -$0.29 EPS loss, and TTM revenue was $0M.
At a glance
C++ balance sheet — some cracks in the foundation
-$18.00 fy2024 eps est
1.2 beta
~$16M market cap
small cap
xvary composite: 32/100 — weak
What they do
Reviva is a 14-person biotech developing drug candidates for schizophrenia and other hard-to-treat diseases.
Brilaroxazine is in Phase III, meaning late human testing, for schizophrenia. RP1208 is pre-clinical, meaning lab work before human tests. That is one late-stage shot versus one lab-stage backup. You are backing a 14-person team with 1 lead asset and 7 prior Phase I uses.
How they make money
n/a
annual revenue
Central nervous system
$0M
Respiratory
$0M
Cardiovascular
$0M
Metabolic
$0M
Inflammatory
$0M
The products that matter
late-stage schizophrenia drug candidate
Brilaroxazine
only clinical asset · targets an $8.18B market
it is the entire company in practical terms. Reviva has $0 revenue today, and this single asset is its only visible path from research spend to product sales.
one-asset bet
Key numbers
$2.88
share price
At $2.88, the stock trades like a stub. That is what a $16M company looks like.
$16M
market value
A $16M market cap leaves almost no room for a bad trial.
1.2
volatility
A 1.2 beta means the stock moves more than the market.
14
headcount
Fourteen employees is a tiny base for a Phase III company.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for RVPH right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Reviva’s latest quarter showed a -$0.29 EPS loss, and TTM revenue was $0M.
This is still a clinical-stage company, so product sales are not the story. The numbers show a $0M revenue base and a quarterly loss that has to be funded somehow.
$0M
ttm revenue
-$0.29
latest eps
-$0.24
trailing eps
latest EPS
The latest quarter loss of -$0.29 matters because there is still no revenue to offset it.
source: EDGAR and Yahoo Finance, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Phase 3 failure for brilaroxazine. This is a one-asset biotech, so a clinical miss and a financing problem land on the same tiny equity at the same time.
med
Phase 3 failure
Brilaroxazine is the only clinical asset highlighted on this page. A negative late-stage result would remove the only visible path from $0 revenue to an actual product.
At a roughly $16M market cap, the equity could lose most of what is left of the thesis in one readout.
med
Cash burn and dilution
The company posted a trailing net loss of -$22.76M and raised $9M in September 2025. That tells you outside capital is already doing real work.
If the timeline stretches or trial costs rise, more equity issuance can dilute you before any commercial value exists.
med
Reverse split does not solve weak demand
The 1-for-20 reverse split helps with listing compliance. It does not change the company's pre-revenue status or the market's view of execution risk.
You can end up with a higher per-share price and the same fragile business underneath it.
med
There is no fallback business
No product revenue, no broad pipeline on this page, no second earnings engine. If timelines slip, there is very little diversification inside the story.
One molecule carries the whole valuation case. That is concentration risk with nowhere to hide.
At roughly $16M against a trailing loss of -$22.76M, RVPH has to clear both science risk and financing risk before you can even start modeling a real business.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
brilaroxazine Phase 3 timing
Results are expected in 2026 based on this snapshot. That is the event that creates a business or ends the story.
cash
losses versus market value
The trailing net loss is -$22.76M against a market cap of roughly $16M. Watch whether funding needs outrun the equity story.
structure
reverse split aftermath
The 1-for-20 reverse split solves compliance pressure for now, but it also reminds the market how weak the stock has been.
update
march 23, 2026 company report
You want two answers: did the trial timeline move, and does management sound more focused on science or on keeping the balance sheet alive.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for RVPH is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive